SILVER SPRING
Tecentriq cleared for adjuvant bladder cancer with ctDNA guidance
- Sponsor
- Genentech $RHHBY
- Drug
- Tecentriq · atezolizumab
- Indication
- muscle-invasive bladder cancer
FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.
What this means
Tecentriq is an immunotherapy drug that boosts the immune system by blocking a protein that helps cancer cells hide. The FDA approved Tecentriq for use after surgery in muscle-invasive bladder cancer patients whose tumors show signs of lingering cancer DNA in their blood. This decision could help doctors identify which patients may benefit most from the drug and potentially reduce the risk of cancer returning.